Vident Advisory’s Ginkgo Bioworks DNA Stock Holding History

Vident Advisory’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,786	Closed	-$129K	–	1433
2024 Q1	$129K	Sell	2,786 -428	-13%	-$22.2K	﹤0.01%	1271
2023 Q4	$217K	Sell	3,214 -286	-8%	-$17.5K	0.01%	1176
2023 Q3	$253K	Buy	+3,500	New	+$280K	0.01%	1002

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vident Advisory's DNA Position: Q2 2024 in Review

Vident Advisory sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 2,786 shares — an estimated $129K sold.

Vident Advisory first reported a position in DNA in Q3 2023 and held it in 3 quarters. The position peaked at $253K in Q3 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

Vident Advisory reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
Vident Advisory sold 2,786 Ginkgo Bioworks shares in Q2 2024, an estimated $129K.
Vident Advisory first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 3 quarters.
Vident Advisory's Ginkgo Bioworks position peaked at $253K in Q3 2023.
313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Vident Advisory's 13F filing for Q2 2024, filed 14 Aug 2024.